Bendamustine in the treatment of chronic lymphocytic leukemia

Expert Opinion on Orphan Drugs

Volumn 2, Issue 6, 2014, Pages 617-623

  Ujjani, Chaitra ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Bendamustine; Chronic lymphocytic leukemia; Fludarabine; Rituximab; Small molecule kinase inhibitor

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DUVELISIB; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; MEDI 551; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; VENETOCLAX;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DIARRHEA; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EVENT FREE SURVIVAL; FATIGUE; GERIATRIC PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; IMMUNOMODULATION; INFECTION; LEUKOPENIA; LUNG CARCINOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEOPLASM; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; SECOND CANCER; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 84901353855     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.903173     Document Type: Article

References (36)

1. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with Bcell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712. Blood 2003;101:6-14
2. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(974 7):1164-74
4. Cheson BD, Rummel MJ. Bendamustine: rebirth of an Old Drug. J Clin Oncol 2009;27(9):1492-501
5. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-17
6. Bendamustine Prescribing Information. Cephalon, Inc. 2008
7. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007;59(6):759-70
8. Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients (pts) with indolent NHL. Cancer Chemother Pharmacol 2010;66(6):1039-49
9. Weide R. Bendamustine for the treatment of relapsed indolent NHL. Ther Clin Risk Manag 2008;4(4):727-32
10. McCloskey JK, Broome CM, Cheson BD. Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. Clin Adv Hematol Oncol 2013;11(3):184-8
11. Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory CLL. J Cancer Res Clin Oncol 2001;127:48-54
12. Aivado M, Schulte K, Henze L, et al. Bendamustine in the treatment of CLL: results and future perspectives. Semin Oncol 2002;29:19-22
13. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory CLL. Haematologica 2005;90:1357-64
14. Lissitchkov T, Arnaudov G, Peytchev D, et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine in pre-treated patients with B-lymphocytic leukaemia requiring therapy. J Cancer Res Clin Oncol 2006;132:99-104
15. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pretreated low-grade NHL. J Cancer Res Clin Oncol 2002;128:603-9
16. Niederle N, Megdenberg D, Balleisen L, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol 2013;92(5):653-60
17. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreatedpatients with CLL. Br J Haematol 2012;159(1):67-77
18. Fischer K, Cramer P, Busch R, et al. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory CLL. J Clin Oncol 2011;30(26):3559-66
19. Fischer K, Cramer P, Busch R, et al. Bendamustine in Combination With Rituximab for Previously Untreated Patients With CLL. J Clin Oncol 2012;30(26):3209-16
20. Eichhorst B, Fink A-M, Busch R, et al. Chemoimmunotherapy with FCR versus BR in previously untreated and physically fit patients with advanced CLL: results of a planned interim analysis of the CLL10 trial, an international, randomized study Of GCLLSG. Blood (ASH Annual Meetings) 2013;122:abstract 526
21. Cortelezzi A, Sciumè M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. Leukemia 2014;28(3):642-8
22. Offner F, Panagiotidis P, Afanasyev B, et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB 115991. 15th iwCLL 2013;abstract 4.29
23. Goede V, Fischer K, Busch R, et al. Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus RituximabPlus Clb In Patients With CLL and Co- Existing Medical Conditions (Comorbidities): final Stage 2 Results Of The CLL11 Trial. Blood (ASH Annual Meetings) 2013;122:abstract 6
24. Ujjani C, Karim S, Goswami T, et al. Bendamustine and Lenalidomide in Relapsed/Refractory CLL. Blood (ASH Annual Meetings) 2011;118:abstract 4618
25. Cheson BD, Ujjani CS, Karim SM, et al. Bendamustine and lenalidomide in relapsed/refractory lymphoid malignancies. J Clin Oncol (ASCO Annual Meeting) 2011;29(15):abstract 8066
26. Chang J, Zhang C, Kim K, et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed/refractory CLL and small lymphocytic lymphoma. Blood (ASH Annual Meetings) 2012;120:abstract 3647
27. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16
28. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42
29. Wiestner A, Farooqui M, Valdez J, et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukemia patients with 17p deletion. 12th ICML 2013;abstract 008
30. O'brien S, Barrientos J, Flinn I, et al. Combination of the BTK inhibitor PCI-32765 with BR in patients with relapsed/refractory CLL. J Clin Oncol (ASCO Annual Meetings) 2012;30(15):abstract 6515
31. Coutre S, Byrd J, Furman R, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (ASCO Annual Meetings) 2011;29(15):abstract 6631
32. Sharman J, de Vos S, Leonard J, et al. A Phase 1 Study of the Selective PI3K Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory CLL. Blood (ASH Annual Meetings) 2011;118:abstract 1787
33. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in CLL, NHL, and multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:21-7
34. O'Brien S, Furman R, Coutre S, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15(1):48-58
35. O'Brien S, Lamanna N, Kipps T, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K {delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) >=65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol (ASCO Annual Meetings) 2013;31(15):abstract 7005
36. Seymour J, Davids M, Pagel J, et al. Updated results of a Phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 12th ICML 2013;abstract 057